Imugene Limited announced that its CF33 Oncolytic Virus technology will be featured at the renowned Annual Meeting for the Society for Immunotherapy of Cancer (SITC), to be held in San Diego, USA on 1-5 November 2023. As one of the most prestigious immunotherapy events on the calendar, SITC 2023 features cutting-edge research presentations by various experts, oral, and poster abstract presentations and various opportunities for networking and discussion with members of the oncology community. The CF33 technology has been accepted for a Trial-in-Progress Poster titled: A Phase I Safety and Tolerability Study of VAXINIA (CF33-hNIS), a Novel Chimeric Oncolytic Poxvirus, Administered Intratumorally or Intravenously in Adults with Metastatic or Advanced Solid Tumors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.067 AUD | -2.90% | -4.29% | -39.09% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.09% | 337M | |
+44.48% | 55.07B | |
+43.68% | 40.22B | |
-0.86% | 41.79B | |
-7.59% | 28.17B | |
+12.30% | 26.28B | |
-21.83% | 18.93B | |
+7.15% | 13.03B | |
+29.40% | 12.26B | |
+25.15% | 12.21B |
- Stock Market
- Equities
- IMU Stock
- News Imugene Limited
- Imugene Limited's CF33 Oncolytic Virus Study to Be Showcase at SITC Annual Meeting